6-K: Tolebrutinib Meets Primary Endpoint in HERCULES Phase 3 Study, The First and Only to Show Reduction in Disability Accumulation in Non-relapsing Secondary Progressive Multiple Sclerosis
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.